Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation

Or Kakhlon, Hila Manning, William Breuer, Naomi Melamed-Book, Chunye Lu, Gino A Cortopassi, Arnold Munnich, Z. Ioav Cabantchik

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Various human disorders are associated with misdistribution of iron within or across cells. Friedreich ataxia (FRDA), a deficiency in the mitochondrial iron-chaperone frataxin, results in defective use of iron and its misdistribution between mitochondria and cytosol. We assessed the possibility of functionally correcting the cellular properties affected by frataxin deficiency with a siderophore capable of relocating iron and facilitating its metabolic use. Adding the chelator de-feriprone at clinical concentrations to inducibly frataxin-deficient HEK-293 cells resulted in chelation of mitochondrial labile iron involved in oxidative stress and in reactivation of iron-depleted aconitase. These led to (1) restoration of impaired mitochondrial membrane and redox potentials, (2) increased adenosine triphos-phate production and oxygen consumption, and (3) attenuation of mitochondrial DNA damage and reversal of hypersensitivity to staurosporine-induced apoptosis. Permeant chelators of higher affinity than deferiprone were not as efficient in restoring affected functions. Thus, although iron chelation might protect cells from iron toxicity, rendering the chelated iron bioavailable might underlie the capacity of deferiprone to restore cell functions affected by frataxin deficiency, as also observed in FRDA patients. The siderophore-like properties of deferiprone provide a rational basis for treating diseases of iron misdistribution, such as FRDA, anemia of chronic disease, and X-linked sideroblastic anemia with ataxia.

Original languageEnglish (US)
Pages (from-to)5219-5227
Number of pages9
JournalBlood
Volume112
Issue number13
DOIs
StatePublished - Dec 15 2008

Fingerprint

Relocation
Iron
Pharmaceutical Preparations
Friedreich Ataxia
Siderophores
Chelating Agents
Chelation
frataxin
Aconitate Hydratase
Mitochondria
Oxidative stress
Staurosporine
Mitochondrial Membrane Potential
HEK293 Cells
Mitochondrial DNA
Oxygen Consumption
Cytosol
Adenosine
DNA Damage
Restoration

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Kakhlon, O., Manning, H., Breuer, W., Melamed-Book, N., Lu, C., Cortopassi, G. A., ... Cabantchik, Z. I. (2008). Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood, 112(13), 5219-5227. https://doi.org/10.1182/blood-2008-06-161919

Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. / Kakhlon, Or; Manning, Hila; Breuer, William; Melamed-Book, Naomi; Lu, Chunye; Cortopassi, Gino A; Munnich, Arnold; Cabantchik, Z. Ioav.

In: Blood, Vol. 112, No. 13, 15.12.2008, p. 5219-5227.

Research output: Contribution to journalArticle

Kakhlon, O, Manning, H, Breuer, W, Melamed-Book, N, Lu, C, Cortopassi, GA, Munnich, A & Cabantchik, ZI 2008, 'Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation', Blood, vol. 112, no. 13, pp. 5219-5227. https://doi.org/10.1182/blood-2008-06-161919
Kakhlon, Or ; Manning, Hila ; Breuer, William ; Melamed-Book, Naomi ; Lu, Chunye ; Cortopassi, Gino A ; Munnich, Arnold ; Cabantchik, Z. Ioav. / Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. In: Blood. 2008 ; Vol. 112, No. 13. pp. 5219-5227.
@article{8f2ea523df2e4f70a4b8757231db6f99,
title = "Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation",
abstract = "Various human disorders are associated with misdistribution of iron within or across cells. Friedreich ataxia (FRDA), a deficiency in the mitochondrial iron-chaperone frataxin, results in defective use of iron and its misdistribution between mitochondria and cytosol. We assessed the possibility of functionally correcting the cellular properties affected by frataxin deficiency with a siderophore capable of relocating iron and facilitating its metabolic use. Adding the chelator de-feriprone at clinical concentrations to inducibly frataxin-deficient HEK-293 cells resulted in chelation of mitochondrial labile iron involved in oxidative stress and in reactivation of iron-depleted aconitase. These led to (1) restoration of impaired mitochondrial membrane and redox potentials, (2) increased adenosine triphos-phate production and oxygen consumption, and (3) attenuation of mitochondrial DNA damage and reversal of hypersensitivity to staurosporine-induced apoptosis. Permeant chelators of higher affinity than deferiprone were not as efficient in restoring affected functions. Thus, although iron chelation might protect cells from iron toxicity, rendering the chelated iron bioavailable might underlie the capacity of deferiprone to restore cell functions affected by frataxin deficiency, as also observed in FRDA patients. The siderophore-like properties of deferiprone provide a rational basis for treating diseases of iron misdistribution, such as FRDA, anemia of chronic disease, and X-linked sideroblastic anemia with ataxia.",
author = "Or Kakhlon and Hila Manning and William Breuer and Naomi Melamed-Book and Chunye Lu and Cortopassi, {Gino A} and Arnold Munnich and Cabantchik, {Z. Ioav}",
year = "2008",
month = "12",
day = "15",
doi = "10.1182/blood-2008-06-161919",
language = "English (US)",
volume = "112",
pages = "5219--5227",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation

AU - Kakhlon, Or

AU - Manning, Hila

AU - Breuer, William

AU - Melamed-Book, Naomi

AU - Lu, Chunye

AU - Cortopassi, Gino A

AU - Munnich, Arnold

AU - Cabantchik, Z. Ioav

PY - 2008/12/15

Y1 - 2008/12/15

N2 - Various human disorders are associated with misdistribution of iron within or across cells. Friedreich ataxia (FRDA), a deficiency in the mitochondrial iron-chaperone frataxin, results in defective use of iron and its misdistribution between mitochondria and cytosol. We assessed the possibility of functionally correcting the cellular properties affected by frataxin deficiency with a siderophore capable of relocating iron and facilitating its metabolic use. Adding the chelator de-feriprone at clinical concentrations to inducibly frataxin-deficient HEK-293 cells resulted in chelation of mitochondrial labile iron involved in oxidative stress and in reactivation of iron-depleted aconitase. These led to (1) restoration of impaired mitochondrial membrane and redox potentials, (2) increased adenosine triphos-phate production and oxygen consumption, and (3) attenuation of mitochondrial DNA damage and reversal of hypersensitivity to staurosporine-induced apoptosis. Permeant chelators of higher affinity than deferiprone were not as efficient in restoring affected functions. Thus, although iron chelation might protect cells from iron toxicity, rendering the chelated iron bioavailable might underlie the capacity of deferiprone to restore cell functions affected by frataxin deficiency, as also observed in FRDA patients. The siderophore-like properties of deferiprone provide a rational basis for treating diseases of iron misdistribution, such as FRDA, anemia of chronic disease, and X-linked sideroblastic anemia with ataxia.

AB - Various human disorders are associated with misdistribution of iron within or across cells. Friedreich ataxia (FRDA), a deficiency in the mitochondrial iron-chaperone frataxin, results in defective use of iron and its misdistribution between mitochondria and cytosol. We assessed the possibility of functionally correcting the cellular properties affected by frataxin deficiency with a siderophore capable of relocating iron and facilitating its metabolic use. Adding the chelator de-feriprone at clinical concentrations to inducibly frataxin-deficient HEK-293 cells resulted in chelation of mitochondrial labile iron involved in oxidative stress and in reactivation of iron-depleted aconitase. These led to (1) restoration of impaired mitochondrial membrane and redox potentials, (2) increased adenosine triphos-phate production and oxygen consumption, and (3) attenuation of mitochondrial DNA damage and reversal of hypersensitivity to staurosporine-induced apoptosis. Permeant chelators of higher affinity than deferiprone were not as efficient in restoring affected functions. Thus, although iron chelation might protect cells from iron toxicity, rendering the chelated iron bioavailable might underlie the capacity of deferiprone to restore cell functions affected by frataxin deficiency, as also observed in FRDA patients. The siderophore-like properties of deferiprone provide a rational basis for treating diseases of iron misdistribution, such as FRDA, anemia of chronic disease, and X-linked sideroblastic anemia with ataxia.

UR - http://www.scopus.com/inward/record.url?scp=58149402407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149402407&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-06-161919

DO - 10.1182/blood-2008-06-161919

M3 - Article

C2 - 18796625

AN - SCOPUS:58149402407

VL - 112

SP - 5219

EP - 5227

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -